Effect and mechanism of Banxia Xiexin decoction in colorectal cancer: A network pharmacology approach

• Published in: Phytomedicine (Stuttgart) Vol. 123; p. 155174
• Main Authors: Wang, Yi, Zhao, Tong, Huang, Chuyue, Liu, Fei, Zhang, Yang, Kong, Desong, Fan, Zhimin
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2024
• Subjects: Animals; Colorectal Neoplasms - drug therapy; Drugs, Chinese Herbal - pharmacology; Humans; Mammals; Mice; Mice, Nude; Molecular Docking Simulation; Network Pharmacology; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Network pharmacology; PI3K/AKT/mTOR; Banxia Xiexin decoction; Colorectal cancer
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2023.155174

Banxia Xiexin decoction (BXD) is a traditional Chinese medicine with anti-colorectal cancer (CRC) activity. However, its bioactive constituents and its mechanism of action remain unclear. Herein, we explored the mechanism of action of BXD against CRC using a network pharmacology approach. First, the targets of the main chemical components of BXD were predicted and collected through a database, and the intersection of compound targets and disease targets was obtained. Subsequently, protein-protein interaction network analysis, Gene Ontology enrichment, and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed to explore the potential mechanisms underlying the effects of BXD on CRC. Finally, a CRC cell model and a CRC xenograft model in nude mice were utilized to further determine the mechanism of action. A compound-therapeutic target network of BXD was constructed, revealing 146 cellular targets of BXD. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling axis was identified as the main target of BXD. Using in vitro and in vivo models, the activity of BXD against CRC was found to be mediated through ferritinophagy by targeting the PI3K/AKT/mTOR axis, leading to intracellular iron accumulation, reactive oxygen species activation, and finally ferroptosis. Through the application of network pharmacology and in vitro/in vivo validation experiments, we discovered that BXD exerts anti-CRC effects via the ferritinophagy pathway. Furthermore, we elucidated the potential mechanism underlying its induction of ferritinophagy. These findings demonstrate the significant potential of traditional drugs in managing CRC and support their wider clinical application in combination chemotherapy, targeted therapy, and immunotherapy.